Skröder Carl, Hellkvist Laila, Westin Ulla, Sahlstrand-Johnsson Pernilla, Hansson Kerstin, Karlsson Agneta, Dahl Åslög, Bjermer Leif, Cardell Lars Olaf
Department of Otorhinolaryngology, Head & Neck Surgery, Skane University Hospital, Lund, Sweden.
Division of ENT Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Clin Transl Allergy. 2025 Jan;15(1):e70017. doi: 10.1002/clt2.70017.
Seasonal allergic rhinitis (AR) impacts public health by affecting work productivity and quality of life. The Swedish tree pollen season starts in February with alder and hazel pollination, followed by birch and ends with oak in May. Systemic corticosteroids are often prescribed when topical treatments fail, despite limited evidence supporting their efficacy.
To compare the effectiveness of prednisolone tablets versus antihistamine tablets in reducing symptoms and medication usage in patients with moderate to severe tree pollen-induced AR.
This interventional single-center, double-blinded randomized trial included 34 patients. Treatment was initiated, and symptoms were registered during the tree pollen season. The two groups received either prednisolone tablets (20 mg) or ebastine tablets (20 mg) for 7 days. Treatment effects were evaluated by comparing daily symptom scores, use of topical medication, and a combined symptom-medical score between the groups. Quality of life was recorded at the start and after 3 weeks.
Both interventions demonstrated efficacy in enhancing quality of life metrics. The area under the curve (AUC) for the combined symptom severity and medication usage score averaged 34.0 (SD = 19.1, 95% CI = 24.5-43.4) in the group treated with prednisolone. This was marginally lower than the control group, with an AUC of 32.6 (SD = 13.2, 95% CI = 25.6-39.7). The difference was not statistically significant (p = 0.80). Both groups exhibited only mild adverse events, which were statistically comparable in frequency and severity.
Prednisolone tablets did not show superior efficacy over antihistamine tablets in reducing symptoms or medication usage in tree pollen-induced AR. These results suggest that systemic corticosteroids may not provide additional benefits over antihistamines, and clinicians should prioritize individualized treatment based on patient preferences and tolerability.
季节性变应性鼻炎(AR)通过影响工作效率和生活质量对公众健康产生影响。瑞典的树花粉季节始于2月的桤木和榛树授粉,随后是桦树,5月以橡树授粉结束。尽管支持全身用糖皮质激素疗效的证据有限,但当局部治疗无效时,仍经常开具此类药物。
比较泼尼松龙片与抗组胺药在减轻中重度树花粉诱发的AR患者症状及减少药物使用方面的有效性。
这项单中心、双盲干预性随机试验纳入了34例患者。在树花粉季节开始治疗并记录症状。两组分别服用泼尼松龙片(20mg)或依巴斯汀片(20mg),疗程7天。通过比较两组的每日症状评分、局部用药情况以及综合症状-药物评分来评估治疗效果。在开始时和3周后记录生活质量。
两种干预措施均显示出改善生活质量指标的疗效。泼尼松龙治疗组综合症状严重程度和药物使用评分的曲线下面积(AUC)平均为34.0(标准差=19.1,95%置信区间=24.5-43.4)。略低于对照组,对照组AUC为32.6(标准差=13.2,95%置信区间=25.6-39.7)。差异无统计学意义(p=0.80)。两组均仅出现轻度不良事件,其频率和严重程度在统计学上具有可比性。
在减轻树花粉诱发的AR患者症状或减少药物使用方面,泼尼松龙片并未显示出优于抗组胺药的疗效。这些结果表明,全身用糖皮质激素可能并不比抗组胺药有更多益处,临床医生应根据患者的偏好和耐受性优先考虑个体化治疗。